JPRN-jRCTs021200019招募中未知
Clinical evaluation on usefulness and safety of a new PET probe [18F]SMBT-1 in Alzheimer's disease and Progressive supranuclear palsy - PETSMBT1ADPSP
Tashiro Manabu0 个研究点目标入组 24 人开始时间: 2020年8月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 60age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •Alzheimer's disease (AD) group
- •(1) Informed consent by the participant or by the substitue (native Japanese)
- •(2) Ages: 60 to 85 years old
- •(3) Alzheimer's disease (AD), Progressive Supranulcear Palsy (PSP), Aged normal control (AN)
- •(4) Those who were judged positive in [11C]PiB PET for screening
- •(5) Those who can tolerate relatively long PET examination (up to 2 hours)
- •Progressive Supranulcear Palsy (PSP) group
- •(1) Informed consent by the participant or by the substitue (native Japanese)
- •(2) Ages: 60 to 85 years old
- •(3) Alzheimer's disease (AD), Progressive Supranulcear Palsy (PSP), Aged normal control (AN)
- •(4) Those who were judged negative in [11C]PiB PET for screening
- •(5) Those who can tolerate relatively long PET examination (up to 2 hours)
- •Aged control (AC) group
- •(1) Informed consent by the participant or by the substitue (native Japanese)
- •(2) Ages: basically 60 to 85 years old (If not available, 40 to 60 can be also acceptable)
- •(3) MMSE scores higher than 24
- •(4) Wechsler memory Scale-R Logical memory II scores higher than cut-off (>3 for those who have education period of 0-7 years; >5 for education period of 8-15 years; >9 for education period of more than 16 years
- •(5) Those who were judged negative in [11C]PiB PET for screening
- •(6) Those who can tolerate relatively long PET examination (up to 2 hours)
排除标准
- •AD group and PSP group
- •(1) Other neurological disorders (including cerebrovascular disorders), drug addicts, alcoholism, as well as severe cardiavascular diseases
- •(2) Administration of irreversible MAO-B inhibitors
- •(3) Habitual smoking (including those who have smoked within 1 year)
- •(4) Severe allergic reactions to drugs and foods
- •(5) Psychiatric disorders, which may make the participation to this study difficult
- •(6) Taboo conditions for MRI examinations (cardiac pacemaker, intracorpoporial metals, etc. to be checked with questionnaire in advance)
- •(7) Systemic circulatory and metabolic disorders as well as organ dysfuctions, such as diabetes melitus, hypertension, endocrinological disorders, congestive heart failure, angina petoris, severe renal dysfunctions with Ccr<30mL/min or under plasmapheresis)
- •(8) Being diagnosed or treated for malignant diseases within 1 year
- •(9) Any sociomedial conditions, which may make the participation to this study difficult
- •(1) Any neurological disorders
- •(2) drug addicts including alcoholism
- •(3) Habitual smoking (including those who have smoked within 1 year)
- •(4) Severe allergic reactions to drugs and foods
- •(5) Psychiatric disorders, which may make the participation to this study difficult
- •(6) Taboo conditions for MRI examinations (cardiac pacemaker, intracorpoporial metals, etc. to be checked with questionnaire in advance)
- •(7) Systemic circulatory and metabolic disorders as well as organ dysfuctions, such as diabetes melitus, hypertension, endocrinological disorders, congestive heart failure, angina petoris, severe renal dysfunctions with Ccr<30mL/min or under plasmapheresis)
- •(8) Being diagnosed or treated for malignant diseases within 1 year
- •(9) Any sociomedial conditions, which may make the participation to this study difficult
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the safety and efficacy of the product in subjects experiencing hair lossCTRI/2018/03/012303Dabur Research Foundation
招募中
3 期
A clinical study to evaluate the efficacy and safety of the Vamana karma followed with two Rasayanas Takradhara and Rasaoushadi in treatment of psoriasis.CTRI/2016/02/006631Central council for Research in Ayurvedic sciences CCRAS110
已完成
3 期
Evaluation of the Clinical Safety and Efficacy of Suprimun in Renal Transplant RecipientsComparative Interventional Treatment for reduceing the renal transplant rejection.kidney transplant rejectionIRCT2013012612274N1Vice-Chancellor for Research, Shahid Beheshti University of Medical Sciences100
已完成
3 期
Evaluation of the Clinical Safety and Efficacy of Suprimun in Renal Transplant RecipientsComparative Interventional Treatment for reduceing the renal transplant rejection.kidney transplant rejectionIRCT2014072118548N1Research Deputy of Kermanshah University Of Medical Sciences60
已完成
不适用
Clinical evaluation of the efficacy and safety of Hochuekkito for fatigue in patients with myeloproliferative neoplasmsmyeloproliferative neoplasmsJPRN-UMIN000031519Department of Hematology, Juntendo University School of Medicine110